Alphatec (NASDAQ:ATEC) and Delcath Systems (OTCMKTS:DCTH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
Earnings & Valuation
This table compares Alphatec and Delcath Systems’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Alphatec||$91.69 million||2.01||-$28.98 million||($0.58)||-6.79|
|Delcath Systems||$2.71 million||0.78||-$45.11 million||N/A||N/A|
This table compares Alphatec and Delcath Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Alphatec has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Alphatec and Delcath Systems, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Alphatec currently has a consensus target price of $4.00, indicating a potential upside of 1.52%. Given Alphatec’s higher probable upside, equities research analysts plainly believe Alphatec is more favorable than Delcath Systems.
Institutional & Insider Ownership
14.8% of Alphatec shares are owned by institutional investors. 44.4% of Alphatec shares are owned by company insiders. Comparatively, 0.0% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Alphatec beats Delcath Systems on 10 of the 11 factors compared between the two stocks.
Alphatec Holdings, Inc., a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures. The company offers MIS products consisting of Battalion Lateral Spacer System and Squadron Lateral Retractor, Illico Minimally Invasive Surgery System, and BridgePoint Spinous Process Fixation System; and fixation products, such as Arsenal Screw System and Zodiac Spinal Fixation Systems. It also provides cervical and cervico-thoracic products, including Trestle Luxe Anterior Cervical Plate System, and Solanas Posterior Cervico/Thoracic Fixation System and Avalon Occipital Plate; and interbody Systems, such as Battalion Universal Spacer System, Novel PEEK and Titanium Spinal Spacers, and Alphatec Solus Locking ALIF Spinal Spacer. In addition, the company offers biologics consisting of AlphaGraft Structural Allograft Spacers, AlphaGraft ProFuse Demineralized Bone Scaffold, Amnioshield Amniotic Tissue Barrier, Alphagraft Demineralized Bone Matrix, and Neocore Osteoconductive Matrix. It sells its products through a network of independent distributors and direct sales representatives in the United States. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.